drugset / Trial / NCT02975037
Evaluation of Metabolic Markers for the Prediction of DDI of Various CYP3A Substrates and Inhibitors
RandomizedParallel-groupOpen-labelBasic science
Summary
Evaluation and validation of metabolic markers for the prediction of drug-drug interaction of various CYP3A4 substrates (sildenafil) and inhibitors (erythromycin/itraconazole) in healthy male subjects
Timeline
- Start
- 2017-02-06
- Primary completion
- 2017-03-04
- Completion
- 2017-06-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clarithromycin | Small molecule | 250 mg | Oral |
| Subject | Itraconazole | Small molecule | 100 mg | Oral |
| Subject | Sildenafil | Unknown | 25 mg | Oral |
Indications
No indication recorded.